Callan Family Office’s Boston Scientific BSX Stock Holding History

Callan Family Office’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.96M	Sell	31,274 -23,752	-43%	-$1.9M	0.04%	362
2025 Q4	$5.25M	Buy	55,026 +22,519	+69%	+$2.21M	0.11%	184
2025 Q3	$3.17M	Buy	32,507 +4,110	+14%	+$426K	0.1%	208
2025 Q2	$3.05M	Buy	28,397 +21,203	+295%	+$2.15M	0.1%	218
2025 Q1	$726K	Sell	7,194 -1,404	-16%	-$141K	0.05%	255
2024 Q4	$768K	Buy	+8,598	New	+$757K	0.05%	293

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Callan Family Office's BSX Position: Q1 2026 in Review

Callan Family Office reduced its Boston Scientific (BSX) stake by 43% in Q1 2026, selling an estimated $1.9M and leaving 31,274 shares worth $1.96M. The position accounts for 0.04% of the portfolio, ranked #362.

Callan Family Office first reported a position in BSX in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.25M in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Callan Family Office held 31,274 shares of Boston Scientific worth $1.96M as of Q1 2026.
Callan Family Office sold 23,752 Boston Scientific shares in Q1 2026, an estimated $1.9M.
Boston Scientific made up 0.04% of Callan Family Office's portfolio in Q1 2026, its #362 holding.
Callan Family Office first reported a position in Boston Scientific in Q4 2024 and has held it in 6 quarters since.
Callan Family Office's Boston Scientific position peaked at $5.25M in Q4 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.